Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

9.475 +2.545 (+36.72%)
Streaming Delayed Price Updated: 2:11 PM EDT, Aug 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? ↗
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry. 
Via The Motley Fool
News headline image
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD ↗
To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under... 
Via Talk Markets
News headline image
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD ↗
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
Via Talk Markets
News headline image
3 Biotech Stocks That Can Gain Exponentially By Leveraging AI ↗
Although fraught with risk, these biotech exposures bring enormous upside potential. 
Via Talk Markets
News headline image
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Largest Clinical-Stage BioTech Drug Stocks Declined 6% ↗
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... 
Via Talk Markets
News headline image
AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th ↗
The global 
Via Talk Markets
News headline image
Down 57%, Is AbCellera Biologics a Buy on the Dip? ↗
Wall Street analysts say this drug developer can more than double your money. 
Via The Motley Fool
News headline image
AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week ↗
The global 
Via Talk Markets
News headline image
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week ↗
This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our... 
Via Talk Markets
News headline image
A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In ↗
The drug development process is very expensive and time-consuming which creates a huge shortage in drug candidates and programs but the advent of AI can significantly shorten and cheapen this process... 
Via Talk Markets
Topics Artificial Intelligence
News headline image
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week ↗
Via Talk Markets
News headline image
3 Stock Gems Hiding in the Nasdaq ↗
If you don’t mind taking a risk in the discount section, these undervalued Nasdaq stocks just might surprise some folks. 
Via InvestorPlace
News headline image
5 Of 7 AI Categories Rose, Slightly,Over Past Week ↗
The 7 AI categories we track went up marginally (1.0%, on average) the second week of May, after having gone down 0.4% the previous week. 
Via Talk Markets
Topics Artificial Intelligence
News headline image
AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript ↗
ABCL earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
ABCL Stock Earnings: AbCellera Biologics Beats EPS, Misses Revenue for Q1 2024 ↗
ABCL stock results show that AbCellera Biologics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
AbCellera Reports Q1 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May ↗
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. 
Via Talk Markets
News headline image
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week ↗
A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and... 
Via Talk Markets
News headline image
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD ↗
The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases. 
Via Talk Markets
Topics Artificial Intelligence
News headline image
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
From AbCellera Biologics Inc.
Via Business Wire
News headline image
The 7 Best Penny Stocks to Buy in Q2 2024 ↗
Discover seven penny stocks to buy primed for significant gains in Q2 2024. Don't miss out on these picks or your portfolio could suffer. 
Via InvestorPlace
News headline image
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Recap: These 7 Artificial Intelligence (AI) Stock Categories Had Returns From +2 To +15% In February ↗
This article is a recap of how 7 artificial intelligence stock categories did in February, and YTD, compared to each other to help you make prudent investment decisions accordingly. 
Via Talk Markets
Topics Artificial Intelligence
News headline image
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD ↗
Grand View Research says the global 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.